A5088684591- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Glioma Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Ferroptosis and cancer prognosis
- Radiomics and Machine Learning in Medical Imaging
- Renal and related cancers
- CAR-T cell therapy research
- Cancer Genomics and Diagnostics
- MRI in cancer diagnosis
- Mathematical Biology Tumor Growth
- Bladder and Urothelial Cancer Treatments
- Monoclonal and Polyclonal Antibodies Research
- CNS Lymphoma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Neuroblastoma Research and Treatments
- Retinal and Optic Conditions
- Adrenal and Paraganglionic Tumors
- Advanced Neuroimaging Techniques and Applications
- Hippo pathway signaling and YAP/TAZ
- Peptidase Inhibition and Analysis
- Sphingolipid Metabolism and Signaling
- Nanoplatforms for cancer theranostics
- Fetal and Pediatric Neurological Disorders
- Acute Ischemic Stroke Management
Vita-Salute San Raffaele University
2017-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2017-2024
Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
2017-2024
Harvard University
2015-2023
Brigham and Women's Hospital
2014-2023
IRCCS Ospedale San Raffaele
2017-2023
San Raffaele University of Rome
2016-2021
Università Campus Bio-Medico
2012-2015
PD-L1 expression in primary clear-cell renal cell carcinoma (ccRCC) increases the likelihood of response to anti-PD-1 inhibition, but fails identify all responders. We hypothesized that levels assessed randomly selected areas tumors may not accurately reflect metastatic lesions, which are target systemic therapy. Therefore, we compared a series ccRCC and their metastases. Tissue blocks from 53 ccRCCs 76 corresponding metastases were retrieved. Areas with predominant highest nuclear grade...
Blocking the programmed death-1 (PD-1) pathway has clinical benefit in metastatic cancer and led to approval of mAbs pembrolizumab nivolumab treat melanoma for non-small cell lung cancer. Expression PD-L1 on surface either tumor cells or infiltrating immune is associated with a higher likelihood response PD-1 blockade multiple studies. Most use are directed its extracellular domain immunohistochemically stain tissue mixture cytoplasmic membrane staining. Cytoplasmic staining obscures...
Glioblastoma multiforme (GBM) is the most common and lethal brain tumor characterized by a strongly immunosuppressive microenvironment (TME) that represents barrier also for development of effective immunotherapies. The possibility to revert this hostile TME immunoactivating cytokines hampered severe toxicity associated with their systemic administration. Here, we exploited lentiviral vector–based platform engineer hematopoietic stem cells ex vivo aim releasing, via tumor-infiltrating...
<h3>Background</h3> Adrenocortical carcinoma (ACC) is a rare tumor in which prognostic factors are still not well established. Programmed Death Ligand-1 (PD-L1) expression ACC and its association with clinico-pathological features survival outcomes unknown. <h3>Methods</h3> Formalin-fixed paraffin-embedded (FFPE) specimens were obtained from 28 patients ACC. PD-L1 was evaluated by immunohistochemistry (IHC) both cell membrane infiltrating mononuclear cells (TIMC). positivity on defined as...
Abstract Purpose: VEGFR2 tyrosine kinase inhibition (TKI) is a valuable treatment approach for patients with metastatic renal cell carcinoma (RCC). However, resistance to inevitable. Identification of novel targets could lead better TKI-naïve or -resistant RCC. Experimental Design: In this study, we performed transcriptome analysis VEGFR TKI-resistant tumors in murine model and discovered that the SPHK–S1P pathway upregulated at time resistance. We tested sphingosine-1-phosphate (S1P) using...
hERG1 channels are aberrantly expressed in human cancers. The expression, functional role and clinical significance of pancreatic ductal adenocarcinoma (PDAC) is lacking. expression was tested PDAC primary samples assembled as tissue microarray by immunohistochemistry using an anti-hERG1 monoclonal antibody (α-hERG1-MoAb). studied cell lines cultures. ERG1 during progression Pdx-1-Cre,LSL-KrasG12D/+,LSL-Trp53R175H/+ transgenic (KPC) mice. vivo determined optical imaging Alexa-680-labelled...
Abstract Metastatic urothelial carcinoma (mUC) has a very high mutational rate and is associated with an APOBEC mutation signature. We examined the correlation of expression overall survival (OS) PD-L1 in cohort 73 mUC patients. mRNA APOBEC3 family genes (A3A, A3B, A3C, A3F_a, A3F_b, A3G, A3H) was measured using Nanostring. expression, evaluated by immunohistochemistry, on tumor infiltrating mononuclear cells (TIMCs) scored from 0 to 4, 2–4 being positive. Wilcoxon’s non-parametric tests...
467 Background: Clinical trials evaluating anti-PD-1 and anti-PD-L1 antibodies (Abs) in ccRCC have shown promising efficacy a subset of patients. Preliminary studies demonstrated that tumor PD-L1 expression increases the likelihood benefit with Ab, but fails to identify all responders. One potential explanation for these results is predictive biomarkers are usually evaluated primary tumors, which more readily available; however, biomarker nephrectomy samples may not accurately reflect...
Treatment of metastatic renal cell carcinoma (mRCC) with agents that block signaling through vascular endothelial growth factor receptor 2 (VEGFR2) induces disease regression or stabilization in some patients; however, these responses tend to be short-lived. Therefore, development combination therapies can extend the efficacy VEGFR antagonists mRCC remains a priority.We studied murine xenograft models RCC become refractory treatment tyrosine kinase inhibitor (TKI) sunitinib. Dalantercept is...
The interplay between cancer cells and the immune system is crucial in progression treatment. In this regard, tumor microenvironment macroenvironment, marked by systemic inflammation markers TILs, could be considered key prognostic factors tumors, including oral lung squamous cell carcinoma. We conducted a retrospective clinical study on patients with Oral Squamous Cell Carcinoma (OSCC) Lung (LUSCC), examining stages, comorbidities, treatments, outcomes. evaluated significance of...
In preclinical models, c-Met promotes survival of renal cancer cells through the regulation programmed death-ligand 1 (PD-L1). However, this relationship in human clear cell carcinoma (ccRCC) is not well characterized. We evaluated expression ccRCC patients using paired primary and metastatic samples assessed association with PD-L1 other clinical features. Areas predominant highest Fuhrman nuclear grade (FNG) were selected. was by IHC an anti-Met monoclonal antibody (MET4 Ab) calculated a...
Tumor heterogeneity poses major clinical challenges in high-grade gliomas (HGGs). Quantitative radiomic analysis with spatial tumor habitat clustering represents an innovative, non-invasive approach to represent and quantify microenvironment heterogeneity. To date, imaging has been applied mainly on conventional magnetic resonance (MRI), although virtually extendible any modality, including advanced MRI techniques such as perfusion diffusion well positron emission tomography (PET) imaging....
424 Background: Programmed death-1 (PD-1) receptor negatively regulates T cell-mediated responses.PD-1 ligand (PD-L1) is aberrantly expressed in clear cell renal carcinoma (ccRCC) and associated with worse prognosis. Levels of PD-L1 expressions non-ccRCC its association clinicopathological features survival are unknown. Methods: Formalin-fixed paraffin-embedded (FFPE) specimens were obtained from 97 patients chromophobe (CHR), papillary (PAP), translocation Xp11.2 (TrL) RCC oncoytoma (ONC)...
Background To investigate the correlation between 18 F-labeled fluoroazomycinarabinoside (18F-FAZA) PET data and hypoxia immunohistochemical markers in patients with high-grade glioma (HGG). Patients methods Prospective study including 20 brain MRI suggestive for HGG undergoing 18F-FAZA PET/CT before treatment assessment. For each scan SUV max , mean tumour volume (FTV) at 40, 50 60% threshold of were calculated; hypoxic was estimated by applying different thresholds (1.2, 1.3 1.4) to...
The aim of this work was to extend the VERDICT-MRI framework for modelling brain tumours, enabling comprehensive characterisation both intra- and peritumoural areas with a particular focus on cellular vascular features. Diffusion MRI data were acquired multiple b-values (ranging from 50 3500 s/mm
4585 Background: Clinical trials evaluating anti-PD-1 and anti-PD-L1 antibodies (Abs) in ccRCC have shown tumor responses a subset of patients. Tumor PD-L1 expression increases the likelihood benefit with Ab, but fails to identify all responders. One explanation for these results is that predictive biomarkers are usually evaluated primary tumors, which may not accurately reflect metastases (mets) targeted by therapy. In this study, we compared series ccRCCs their mets. Methods: Paraffin...
4526 Background: Programmed death-1 (PD-1) receptor negatively regulates T cell-mediated responses.PD-1 ligand (PD-L1) is aberrantly expressed in clear cell renal carcinoma (ccRCC) and associated with worse prognosis. PD-L1 expression its association clinicopathological features/clinical outcome are unknown non-ccRCC benign kidney tumors (BKT). Methods: Formalin-fixed paraffin embedded (FFPE) specimens were obtained from 124 patients (pts) chromophobe RCC (CHR), papillary (PAP),...